IDEXX Laboratories Posts Strong Q1 2026 Growth, Raises Full-Year Outlook
Event summary
- IDEXX Laboratories reported Q1 2026 revenues of $1.14 billion, up 14% year-over-year, with Companion Animal Group (CAG) driving 15% growth.
- Earnings per diluted share (EPS) increased 17% to $3.47, benefiting from tax benefits and currency changes.
- The company raised its full-year revenue guidance to $4.68 billion–$4.76 billion, up from $4.63 billion–$4.72 billion.
- IDEXX Cancer Dx™ platform and IDEXX inVue Dx™ rollout are key growth drivers.
- Operating margin expanded to 31.8%, with strong recurring revenue volume gains and operational productivity.
The big picture
IDEXX Laboratories' strong Q1 2026 performance reflects its leadership in pet healthcare innovation, particularly in diagnostics and software. The company's ability to capitalize on recurring revenue streams and expand its premium instrument installed base positions it well in a growing market. However, sustaining this momentum will depend on continued innovation and effective execution of its growth strategy.
What we're watching
- Innovation Momentum
- The continued adoption of IDEXX Cancer Dx™ and IDEXX inVue Dx™ will be critical to sustaining growth.
- Market Dynamics
- The pace at which clinical visit pressures ease will impact U.S. diagnostic frequency and revenue.
- Execution Risk
- How IDEXX manages operational productivity and R&D investments will affect long-term profitability.
Related topics